An Exploratory Clinical Study of the Safety and Efficacy of Avapritinib Combined With Azacitidine and Venetoclax in the Treatment of Relapsed Acute Myeloid Leukemia After Allogeneic Hematopoietic Stem Cell Transplantation
Latest Information Update: 23 Jan 2025
Price :
$35 *
At a glance
- Drugs Avapritinib (Primary) ; Azacitidine (Primary) ; Venetoclax (Primary)
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- 23 Jan 2025 New trial record